The QualityStocks Daily Friday, September 30th, 2022

Today's Top 3 Investment Newsletters

ChineseWire(FNGR) $3.3700 +82.16%

INO Market Report(GTII) $5.3100 +74.10%

The Stock Dork(SAI) $3.2400 +43.36%

The QualityStocks Daily Stock List

NioCorp Developments Ltd. (NIOBF)

InvestorIntel, QualityStocks and OTC Markets Group reported earlier on NioCorp Developments Ltd. (NIOBF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NioCorp Developments Ltd. is a developer of superalloy metals. The Company is developing a superalloy materials project in Southeast Nebraska. The Project will produce Niobium, Scandium, as well as Titanium. OTCQX-listed, NioCorp Developments is headquartered in Centennial, Colorado.

Niobium is used to produce superalloys and high strength, low alloy steel. Scandium is a superalloy material. It can be combined with aluminum to make alloys with increased strength and improved corrosion resistance. Titanium is used in diverse superalloys.

The Company is developing North America's only niobium/scandium/ titanium project. The Elk Creek Project is the highest-grade niobium project in North America. It is also the largest prospective producer of scandium worldwide. The Elk Creek Project is positioned near Elk Creek, Nebraska.

NioCorp Developments Ltd. (NIOBF), closed Friday's trading session at $1.04, up 24.105%, on 886,978 volume. The average volume for the last 3 months is 913,835 and the stock's 52-week low/high is $0.586/$1.25.

PolarityTE (PTE)

StockMarketWatch, MarketBeat, QualityStocks, BUYINS.NET, Zacks, StreetInsider, Schaeffer's, Trading Concepts, Trades Of The Day and The Online Investor reported earlier on PolarityTE (PTE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PolarityTE Inc. (NASDAQ: PTE) (FRA: NJTC) is a regenerative biomaterials and biotechnology firm which is engaged in the development and commercialization of various regenerative biomaterials and tissue products for the fields of material sciences, biomedical engineering and medicine.

PolarityTE Inc., which changed its name from Majesco Entertainment, is based in Salt Lake City, Utah and was founded on May 8, 1998. The firm serves consumers in the United States.

PolarityTE Inc. operates in 2 segments, i.e. Contract Services and Regenerative Medicine. The firm offers contract research services and is currently pursuing regulatory approval for technology which will use an individual’s tissue substrates to regenerate nerves, blood vessels, fat, cartilage, muscle, bone and skin.

PolarityTE Inc.’s portfolio includes a biologically active allogenic dressing which is used in aesthetics and wound care to speed up the skin’s healing. It is called PTE 11000. There is also a tissue product developed to repair, reconstruct, replace and supplement the skin of patients who need treatment for burns, chronic or acute wounds defects known as SkinTE. The firm also develops an autologous construct that assists in bowel tissue regeneration, BowelTE; a product that addresses causes of liver failure, LiverTE; a product for patients with carpal tunnel syndrome, migraines, craniofacial injuries, chronic compression because of joint replacements or neuromas called NeuralTE; a vascular regeneration product, AngioTE; a cartilage regeneration product, CartTE and a homologous bone regeneration product called OsteoTE.

PolarityTE Inc. uses a biologically sound and natural platform that can readily be adapted to a wide range of tissue systems and organs. This affords an advantage which will allow it to revolutionize the future and field of translational regenerative medicine.

PolarityTE (PTE), closed Friday's trading session at $0.87, up 27.9412%, on 913,835 volume. The average volume for the last 3 months is 3.572M and the stock's 52-week low/high is $0.613/$20.75.

Alset EHome International (AEI)

RedChip, Streetwise Reports, QualityStocks, Wyatt Investment Research, Vantage Wire, Red Chip and BUYINS.NET reported earlier on Alset EHome International (AEI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Alset EHome International Inc. (NASDAQ: AEI) (FRA: 42A0) is a diversified holding firm that is focused on bio-health activities, digital transformation technology and property development in South Korea, Australia, Hong Kong, Singapore and the U.S.

The firm has its headquarters in Bethesda, Maryland and was founded in 2018 on March 7th by Heng Fai Chan. Prior to its name change in February 2021, the firm was known as HF Enterprises Inc. It serves consumers across the globe and was a former subsidiary of Hancock Fabrics Inc.

The enterprise operates through the other, bio-health, digital transformation and property development segments. The property segment takes part in 3rd party development projects while the digital technology segment is involved in mobile app product development and the provision of IT services to service providers, end-users and other commercial users. On the other hand, the other segment is involved in the provision of corporate restructuring, asset management, business development and corporate strategy services, and the bio-health segment helps finance research and sell products that promote healthy lifestyles.

The company, which is involved in sales and rental as well as home building, also designs apps for e-commerce software and enterprise messaging platforms. This is in addition to being involved in the study of nutritional chemistry to develop natural sugar alternatives, supplements and natural foods and also treat immune-related and neurological ailments.

The firm recently entered into a joint venture agreement with Novum Alpha Pte Ltd, to launch new investor-friendly cryptocurrency ETPs to the market. This move will not only generate significant value to Alset’s shareholders but also deepen its position in the digital assets space, which will be good for its growth.

Alset EHome International (AEI), closed Friday's trading session at $0.2562, up 30.8478%, on 3,643,225 volume. The average volume for the last 3 months is 132.416M and the stock's 52-week low/high is $0.185/$2.46.

BrewBilt Manufacturing, Inc. (BBRW)

We reported earlier on BrewBilt Manufacturing, Inc. (BBRW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BrewBilt Manufacturing, Inc. is one of the only California companies that custom designs, hand crafts, and integrates processing, fermentation, and distillation processing systems for the craft beer, cannabis, and hemp industries. The Company uses "Best in Class" U.S. made components integrated with stainless steel processing vessels using only American made steel. BrewBilt Manufacturing’s dedication is to helping build the craft beer community one brewery at a time. Founded in 2014, BrewBilt Manufacturing is headquartered in Grass Valley, California. The Company lists on the OTC Markets.

All BrewBilt Manufacturing products are designed and fabricated as "food grade" quality. This enables the Company to manufacture vessels for food & beverage processing. BrewBilt has been making systems that are pharmaceutical grade for clients involved in distillation for the cannabis and hemp industries over the past 36 months, thus making the revenue potential considerably greater.

The Company works with its clients every step of the way. This is from concept to opening. BrewBilt helps its clients keep on track. This is from working with their bankers on financing solutions, their architect and contractor on equipment layout, to scheduling, logistics, and continuing project management.

BrewBilt provides a six-year material and workmanship warranty on everything it builds. The BrewBilt team includes brewers, design engineers, craftsmen, and owners with greater than 50 years of business experience.

BrewBilt Manufacturing, Inc. (BBRW), closed Friday's trading session at $0.0008, up 33.3333%, on 132,416,203 volume. The average volume for the last 3 months is 130,249 and the stock's 52-week low/high is $0.0005/$0.84.

Vincerx Pharma (VINC)

MarketBeat and QualityStocks reported earlier on Vincerx Pharma (VINC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vincerx Pharma Inc. (NASDAQ: VINC) is a clinical-stage biopharmaceutical firm that is focused on researching and developing therapies for the treatment of cancer.

The firm has its headquarters in Palo Alto, California and was incorporated in 2018, on December 19th by John C. Byrd, Soo In Hwang, Tom C. Thomas, Raquel E. Izumi and Ahmed M. Hamdy. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers around the globe, with a focus on the United States.

The company is focused on addressing the unmet medical needs for treating cancer. It uses its extensive oncology and development expertise to advance new therapies. The company’s pipeline is derived from a license agreement with Bayer.

The enterprise’s product pipeline comprises of a small molecule drug conjugate dubbed VIP236, for the treatment of solid tumors; an oral PTEFb/CDK9 inhibitor known as VIP217; and a cyclin-dependent kinase-9 inhibitor dubbed VIP152, for the treatment of patients with advanced cancer. VIP152 inhibits RNA polymerase II (RNAPII) phosphorylation, which helps prevent transcription elongation and blocks the expression of genes which promote cancer. It also develops VIP924 and VIP943 for the treatment of hematologic malignancies.

The firm recently released preliminary clinical data for its VIP152 candidate and is currently focused on aligning its clinical trial design with the Project Optimus Initiative by the FDA. The success and approval of this formulation will not only benefit patients with different types of cancer but also bring in more investors into the firm.

Vincerx Pharma (VINC), closed Friday's trading session at $1.38, up 25.4545%, on 138,625 volume. The average volume for the last 3 months is 192,260 and the stock's 52-week low/high is $1.00/$17.4899.

Invivyd Inc. (IVVD)

MarketBeat reported earlier on Invivyd Inc. (IVVD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Invivyd Inc. (NASDAQ: IVVD) is a clinical-stage biopharmaceutical firm that is focused on discovering, developing and commercializing antibody-based solutions for infectious illnesses.

The firm has its headquarters in Waltham, Massachusetts and was incorporated in 2020, on June 3rd by Laura Waler, Ren Russo and Tillman U. Gerngross. Prior to its name change in September 2022, the firm was known as Adagio Therapeutics Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company’s mission is to transcend the limitations of the human immune system. It is party to a collaboration agreement with Adimab LLC, which entails discovering and optimizing proprietary antibodies. It is also party to a collaboration agreement with the Scripps Research Institute, which involves research to identify vaccine candidates to diagnose, treat or prevent influenza or beta coronaviruses. The company’s candidates are being developed for use in the treatment and prevention of illnesses, and are optimized for potency and breadth of protection across strains.

The enterprise develops engineered antibodies which offer durable protection from viral infectious illnesses like COVID-19. Its lead product candidate is a neutralizing antibody dubbed Adintrevimab (ADG20), which is undergoing phase 3 trials evaluating its effectiveness in preventing and treating the coronavirus infection.

The company recently announced its name change, with its CEO noting that they remained focused on their strategy to develop antibodies which could better treat viral infections. The approval of its antibodies in the treatment of these infections would not only benefit patients but also bring in additional revenues into the company.

Invivyd Inc. (IVVD), closed Friday's trading session at $3.13, up 3.3003%, on 236,877 volume. The average volume for the last 3 months is 44,060 and the stock's 52-week low/high is $2.41/$78.82.

Endonovo Therapeutics (ENDV)

QualityStocks, NetworkNewsWire, StocksToBuyNow, SmallCapRelations, Tip.us, SeriousTraders, MarketBeat, SeeThruEquity Research, Damn Good Penny Picks, Value Penny Stocks, TheNextBigTrade, HEROSTOCKS, Penny Picks, Penny Stock Newsletter, DSR News, Epic Stock Picks, PREPUMP STOCKS, Innovative Marketing, PHUB News, Stock Commander, Stock Brain, BestDamnPennyStocks, Darth Trader, Hot Stock Profits, Buzz Stocks, OTC Markets Group, Penny Pick Finders, Planet Penny Stocks, SecretStockPromo, SmallCapVoice, StockOnion, The Stock Psycho and PennyStockProphet reported earlier on Endonovo Therapeutics (ENDV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Endonovo Therapeutics Inc. (OTCQB: ENDV) is a biotechnology firm that is focused on developing, manufacturing and distributing non-invasive electroceutical medical devices for regenerative medicine.

The firm has its headquarters in Woodland Hills, California and was incorporated in November 2008. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States.

The company develops and manufactures medical devices which are focused on the healing of wounds and reduction of inflammation, pain and edema. Its devices have been designed to deliver its proprietary electroceutical therapy for the treatment of central nervous system disorders, cardiovascular illnesses and inflammatory conditions.

The enterprise’s offerings include a non-invasive electroceutical therapeutic device dubbed SofPulse, which has been developed for the palliative treatment of chronic wounds, soft tissue injuries, edema and post-op pain. This device has CMS National Coverage for the treatment of chronic wounds. Its electroceuticals medical device is also used in the treatment of inflammation, chronic kidney diseases, other wounds, cardiovascular illnesses, non-alcoholic steatohepatitis, liver illnesses, ischemic stroke and peripheral artery diseases, as well as for central nervous system disorders like multiple sclerosis, post-concussion syndrome, acute concussions and traumatic brain injury.

The company recently signed a definitive agreement to acquire all of the assets and business operations owned by Western Star Concrete LLC. This move will facilitate the company’s expansion into a new market as well as other geographic regions. This will, in turn, significantly increase its profitability and help generate value for its shareholders.

Endonovo Therapeutics (ENDV), closed Friday's trading session at $0.0074, up 5.7143%, on 44,060 volume. The average volume for the last 3 months is 417,951 and the stock's 52-week low/high is $0.006/$0.035.

Quanergy Systems (QNGY)

We reported earlier on Quanergy Systems (QNGY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Quanergy Systems Inc. (NYSE: QNGY) is a technology firm that is focused on developing and marketing LiDAR (light detection and ranging) solutions for IoT and automotive applications.

The firm has its headquarters in Sunnyvale, California and was incorporated in 2012 by Tianyue Yu, Angus Pacala and Louay Eldada. It operates as part of the scientific and technical instruments industry, under the technology sector. The firm serves consumers around the globe.

The company has designed a high-performance AI-powered LiDAR platform to accelerate the automation of key business processes to increase efficiency, productivity and safety of the 3D world.

The enterprise’s products include the M1 LiDAR sensor for mid-long range industrial measurement applications; MQ-8 LiDAR sensor for flow management applications; M8 LiDAR sensor, which offers 3D perception using time-of-flight measurement technology and multiple eye-safe laser beams; M1 Edge 2D LiDAR sensor that enables reliable smart navigation and collision avoidance; and the M8-Prime 3D LiDAR sensor, which offers industry-leading pinpoint accuracy and captures for industrial and mapping applications. It also offers a 3D computer perception software known as QORTEX DTC; an S3 solid state LiDAR sensor; and the QORTEX people counter, which facilitates the development of innovative and accurate people counting and queue management applications.

The company announced recently that it is now officially a part of Network Optix’s Works with Nx Marketplace. This move allows the company to better meet consumer needs while also helping extend its consumer reach in the market, which will positively influence shareholder value and growth.

Quanergy Systems (QNGY), closed Friday's trading session at $0.207, off by 2.5424%, on 417,951 volume. The average volume for the last 3 months is 226,388 and the stock's 52-week low/high is $0.20/$7.15.

TFF Pharmaceuticals (TFFP)

BUYINS.NET, MarketBeat, TradersPro, StreetInsider, StockMarketWatch and QualityStocks reported earlier on TFF Pharmaceuticals (TFFP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TFF Pharmaceuticals Inc. (NASDAQ: TFFP) (FRA: 0K3) is a clinical stage biopharmaceutical firm that is engaged in the development and commercialization of drug products based on its patented technology platform.

The firm has its headquarters in Austin, Texas and was incorporated in 2018, on January 24th. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in Australia and the United States, with a focus on those in the state of Texas.

The company’s Thin Film Freezing technology platform was designed for the development of its inhalation drug products. It is party to a licensing and collaboration agreement with UNION Therapeutics A/S; and a joint development agreement with AugmentaBioworks Inc., which entails the development of an inhaled SARS-CoV-2 monoclonal antibody. The company is also party to a license agreement with the University of Texas at Austin, which involves developing inhaled dry powder drugs.

The enterprise’s product pipeline is comprised of its TFF Voriconazole Inhalation Powder, which has been developed to treat invasive pulmonary aspergillosis; Niclosamide Inhalation Powder for the treatment of tapeworm infections in humans, as well as coronavirus infections; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials evaluating its effectiveness in preventing lung transplant rejection.

The firm recently announced its latest financial results, with its CEO noting that they remained focused on advancing their internal pipeline. The firm is also focused on partnering with more pharma companies, which will not only open it up to new growth opportunities but also bring in additional revenues into the firm.

TFF Pharmaceuticals (TFFP), closed Friday's trading session at $4.06, off by 4.918%, on 226,404 volume. The average volume for the last 3 months is 215,963 and the stock's 52-week low/high is $3.60/$9.96.

VectivBio Holding (VECT)

MarketBeat, TradersPro and Finance Observer reported earlier on VectivBio Holding (VECT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

VectivBio Holding AG (NASDAQ: VECT) is a clinical-stage biopharmaceutical firm that is engaged in discovering, developing and commercializing drugs to treat severe rare conditions.

The firm has its headquarters in Basel, Switzerland and was incorporated in2019, on May 22nd by Luca Santarelli. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States and Switzerland.

The company develops drugs which target the biological root cause of rare conditions with significant unmet medical needs, with the objective of achieving disease-modification. It hopes to meaningfully improve and transform the lives of patients through its therapies.

The enterprise’s product pipeline is comprised of a long-acting synthetic peptide analog of glucagon-like peptide-2 dubbed Apraglutide, which is undergoing phase 3 clinical trials evaluating its effectiveness in treating short bowel syndrome-intestinal failure. This condition impairs an individual’s quality of life and usually results from congenital defects, surgical resection or disease-associated loss of absorption. The candidate is also in phase 2 clinical trials testing its efficacy in treating short bowel syndrome-intestinal failure patients with colon-in-continuity anatomy. This is in addition to being in phase 2 trials evaluating its effectiveness in treating steroid-refractory gastrointestinal acute versus host disease.

The firm remains focused on advancing its Apraglutide formulation, whose success and approval will not only benefit patients with a range of indications but also encourage more investments into the firm. This will in turn help create shareholder value while also bolstering the firm’s overall growth.

VectivBio Holding (VECT), closed Friday's trading session at $6, up 26.0504%, on 215,963 volume. The average volume for the last 3 months is 12.381M and the stock's 52-week low/high is $2.7426/$7.9152.

Rivian Automotive Inc. (RIVN)

Kiplinger Today, InvestorPlace, The Street, QualityStocks, MarketClub Analysis, Schaeffer's, MarketBeat, Daily Trade Alert, The Online Investor, Investopedia, Trades Of The Day, StocksEarning, INO Market Report, Early Bird, Louis Navellier and Zacks reported earlier on Rivian Automotive Inc. (RIVN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

For dozens of countries across the world, electric vehicles represent a chance to fight climate change by curbing soaring carbon emissions. Since EVs run on rechargeable lithium-ion batteries, they produce zero emissions at the tailpipe. Experts have found that they produce significantly fewer emissions compared to traditional cars even if the electricity they use isn’t “clean, making them suitable for economies looking to achieve net-zero emissions by 2050.

However, most consumers have had one main complaint for the past decade or so: EVs are just too expensive. Even with subsidies meant to make EVs less costly, most drivers simply can’t afford the cost of going electric. A recent survey of more than 12,000 drivers in the United Kingdom revealed that soaring energy costs are making electric vehicles more unaffordable than they already are.

Around 63% of the surveyed drivers said that increasing energy costs are now acting as a barrier to buying or owning an EV. The AA survey revealed that spiraling energy costs were the only thing preventing them from purchasing electric cars. It is the latest in a host of polls looking into the wide-ranging effects of the current energy crisis.

The energy crunch can mostly be attributed to the ongoing Russia-Ukraine war and the impact it has had on the regional and global economy. Soon after Russia’s unprovoked invasion of Ukraine, several Western countries rebuked the country and instituted a host of sanctions to harm its war effort.

In retaliation, Russia cut gas flows to the rest of Europe and plunged the region into a crisis that saw energy prices grow to 10 times their five-year average. The energy crisis has hit European countries such as the UK and Germany particularly hard. A Riverdale Leasing survey found that 43% of motorists believed the UK would never be completely ready for a mass transition to electric cars.

In addition, 21% blamed rising energy costs coupled with a higher chance for increased home energy costs as the primary reason. EV charging company Osprey recently announced a major price hike that made its charging network the most expensive in the UK, something that will undoubtedly prevent many drivers from making the switch to electric cars. According to Osprey, it was forced to raise its charging prices due to increased energy costs and the lack of an energy price cap for businesses.

However, one expert says that despite rising energy costs, electric cars are still “considerably cheaper” to run compared to traditional internal combustion engine (ICE) cars. However, given the surge in energy prices, he says, drivers can be forgiven for thinking that running an electric car would be costly.

It now remains up to electric vehicle startups such as Rivian Automotive Inc. (NASDAQ: RIVN) to educate motorists and show them that despite the current high cost of energy, it is still more affordable in the long term to own an EV in lieu of a conventional gas-powered car.

Rivian Automotive Inc. (RIVN), closed Friday's trading session at $32.91, up 1.857%, on 12,381,047 volume. The average volume for the last 3 months is 15.519M and the stock's 52-week low/high is $19.25/$179.4699.

Freeport-McMoRan Inc. (FCX)

MarketClub Analysis, The Street, InvestorPlace, Schaeffer's, Kiplinger Today, SmarTrend Newsletters, StocksEarning, MarketBeat, Barchart, StreetAuthority Daily, Trades Of The Day, StreetInsider, Money Morning, TopStockAnalysts, Investopedia, Daily Trade Alert, Louis Navellier, VectorVest, Zacks, Trading Markets, Marketbeat.com, The Growth Stock Wire, ProfitableTrading, Daily Wealth, The Wealth Report, TheStockAdvisors, Top Pros' Top Picks, Wall Street Elite, StreetAlerts, All about trends, Streetwise Reports, TradingMarkets, Leeb's Market Forecast, The Online Investor, Market FN, QualityStocks, INO.com Market Report, Trading Tips, TheStockAdvisor, Dividend Opportunities, InvestmentHouse, StockTwits, Investor Guide, Investors Alley, Wealth Insider Alert, Investment House, Trading Concepts, InvestorGuide, Options Trader Elite, Market Intelligence Center Alert, Money and Markets, The Best Newsletters, Darwin Investing Network, Energy and Capital, Early Bird, Buttonwood Research, The Motley Fool, Trade of the Week, AnotherWinningTrade, Wealth Daily, Investing Signal, Wyatt Investment Research, Bourbon and Bayonets, MarketWatch, Market Authority, Investor Update, Profit Confidential, Wealthpire Inc., Street Insider, TradingAuthority Daily, Wall Street Daily, Cabot Wealth, Stock Research Newsletter, Super Stock Investor, InvestorsUnderground, AllPennyStocks, CNBC Breaking News, Daily Markets, Uncommon Wisdom, FeedBlitz and Normandy Investment Research reported earlier on Freeport-McMoRan Inc. (FCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gold investors have plenty of reason to worry as prices for the precious metal have continued their downward trend into the last weeks of September. Last week, gold prices hit a two-year low as central banks across the world raised their interest rates alongside the U.S. Federal Reserve to prevent inflation.

With the global economy in a spiral since the COVID pandemic and the Russia-Ukraine war coupled with worldwide shortages and supply chain constraints, the cost of living has risen significantly in recent months. The Fed has gotten increasingly worried about the state of the economy and increased the benchmark interest rate by 0.75 basis points for several consecutive months to forestall inflation. Other central banks followed suit, resulting in a rise in interest rates around the world that impacted gold prices.

U.S. gold futures fell by 1.6% to $1,653 an ounce and spot gold went down by 1.4% to $1,647. Gold bullion also went down for the second consecutive week with a 1.8% drop in prices. The decline in gold prices comes after the U.S. dollar rallied and climbed to a two-decade high in May as fears about the Fed’s ability to forestall economic inflation led to an increase in risk-off sentiment.

OANDA senior analyst Edward Moya stated that gold will remain vulnerable in the short term as long as the dollar keeps trending upward. He added that with the economy “clearly” headed towards recession, elevated hard landing risks have increased flows into the dollar.

While this has been great for the greenback, it has had a dampening effect on dollar-priced gold bullion. Despite its long-standing status as a safe-haven asset, gold has always been sensitive to increasing interest rates in North America as the global economy essentially runs on the greenback. These interest rate hikes result in higher opportunity costs for holding nonyielding gold bullion, boosting the dollar but reducing demand for gold bullion.

Ole Hansen, head of commodity strategy at Saxo Bank, stated that as long as the danger of inflation looms and the market remains hawkish, semi-investment metals such as gold and silver will remain under pressure.

Like gold, other precious metals have experienced sharp drops in prices, with silver going down by 4.1% to $18.84 per ounce and platinum prices dropping by 4.8% to $857.46 per ounce. Palladium, which is mostly used in catalytic converters, saw its price drop by 4.7% to $2065.29 an ounce.

As the economic outlook of different countries continues to dim, gold is likely to regain its appeal, and companies such as Freeport-McMoRan Inc. (NYSE: FCX) will have ample opportunity to further strengthen their balance sheets and offer their shareholders decent returns on investment.

Freeport-McMoRan Inc. (FCX), closed Friday's trading session at $27.33, off by 2.9819%, on 16,108,350 volume. The average volume for the last 3 months is 133,500 and the stock's 52-week low/high is $24.80/$51.99.

The QualityStocks Company Corner

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters’ over-allotment option to purchase 150,000 additional shares of common stock, each at a public offering price of $5.00. Silo Pharma’s common stock began trading on the Nasdaq Capital Market on Sept. 27, 2022, under the symbol SILO. The company secured $5,750,000 million in gross proceeds from the offering, before deducting underwriting discounts and commissions and other expenses. Silo Pharma intends to use the net proceeds for product development, marketing, working capital and general corporate purposes. In addition, a portion of the proceeds may be used for acquisitions of complementary businesses, technologies or other assets. Laidlaw & Company (U.K.) Ltd. acted as sole book-running manager for the offering. To view the full press release, visit https://ibn.fm/nFGPA

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Friday's trading session at $5.38, up 3.9614%, on 133,838 volume. The average volume for the last 3 months is 5,217 and the stock's 52-week low/high is $4.46/$12.445.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, recently received its 27th worldwide patent, granted in Mexico under registration #390001. “The patent applies to a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a wide variety of ready-to-drink consumer retail beverage products. The latest patent provides value to the company through its continued pursuit of gaining regulatory approval for its patented DehydraTECH(TM)-enabled cannabidiol (‘CBD’) for the treatment of hypertension in regulated pharmaceutical applications. This has produced the claims necessary for the Mexico patent to use DehydraTECH-processed non-psychoactive cannabinoids to treat cardiac and cardiometabolic disorders,” a recent article reads. “Additional claims granted to the Mexican patent #390001 include the treatment of neurological diseases, including Alzheimer’s, Parkinson’s, schizophrenia, and human immunodeficiency virus (‘HIV’) dementia. The indications also include obesity, hepatic diseases, diabetes, appetite disorders, cancer chemotherapy, benign prostatic hypertrophy, irritable bowel syndrome, biliary diseases, ovarian disorders, marijuana abuse, and alcohol, opioid, nicotine, or cocaine additions. With the approval of its 27th patent, the company is still working on expanding the indications and efficacy of its DehydraTECH technology – with ~50 pending patents worldwide.” To view the full article, visit https://cnw.fm/JL7GL

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $2.45, up 0.409836%, on 6,072 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $12.445/$.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora Growth is a global cannabis cultivator, product builder, and supplier, experiencing continued growth thanks to strategic acquisitions and an expanding supply chain for marketing its brands in various countries

Flora announced its most recent acquisition in September — a deal to acquire the assets of the No Cap Hemp Co. brand in exchange for payment of 10 percent of the No Cap brand revenues up to a maximum of $2 million

The deal grants Flora an immediate revenue stream free of closing cost considerations

Flora has seen revenues skyrocket over the past year, with a 604 percent YOY increase in the H1 reporting period

Global cannabis cultivator, product manufacturer and distributor Flora Growth (NASDAQ: FLGC) is measuring its success in rapidly rising revenues brought on by strategic acquisitions and the expanding international movement of its brands. Last week, the World Anti-Doping Agency announced that cannabis would remain on its list of banned substances for international athletes. This comes after a scientific review conducted by the agency and a subsequent discussion found that the use of marijuana violated the spirit of sport. Whether a particular drug should be banned is dependent on whether the substance meets at least two out of the three criteria the organization uses in its evaluation. One of those is criteria is violating the spirit of sport. The agency also considers whether a substance represents a health risk to the athlete and whether it has the potential to improve an athlete’s performance. In 2021, advocates urged the organization to enact a reform after Sha’Carri Richardson of the U.S. Olympic team was suspended from taking part in an Olympics event because of a positive THC test. THC is one of the primary psychoactive compounds found in marijuana, the other being CBD. Unlike CBD, however, THC causes individuals to get high. This announcement is sure to be disappointing to athletes who had planned on using state-legal marijuana provided by companies such as Flora Growth Corp. (NASDAQ: FLGC) for medicinal or recreational purposes.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Friday's trading session at $0.7057, up 3.0069%, on 463,094 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.586/$6.29.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) , which develops solutions to optimize and automate the supply chain process, today announced that it has selected the corporate communications expertise of IBN , a multifaceted financial news and publishing company for private and public entities. As part of the client partner relationship, IBN will work to generate greater awareness for Freight Technologies by leveraging its investor based distribution network of 5,000+ key syndication outlets , various newsletters , social media channels , wire services via InvestorWire , blogs and other outreach tools. “Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport. Through Fr8app, Freight Technologies is leveraging AI and machine learning to connect shippers with qualified carriers in real time,” said Chris Johnson, director of client solutions for IBN. “We’re excited to customize our comprehensive suite of corporate communications solutions for Freight Technologies as it works to improve the efficiency and sustainability of cross-border shipping across North America.” To view the full press release, visit https://ibn.fm/EALdp

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.

Fr8University

Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Friday's trading session at $0.5101, up 1.9996%, on 34,802 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.356/$8.734.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) , a company focused on developing clean energy solutions, suggests that emission reductions can be realized by manufacturing green ammonia without the use of fossil fuels and injecting it deep into the ground. “FuelPositive’s flagship product, an on-site, containerized green ammonia production system, uses renewable electricity to synthesize hydrogen from water and nitrogen from the air before combining the molecules in a converter to form green ammonia. In this way, and given there are no carbon emissions related to production, FuelPositive is looking to reduce the carbon emissions linked to the agriculture sector’s use of ammonia,” a recent article reads. “In addition to reducing carbon emissions from ammonia production, FuelPositive is looking to do more by supporting best farming practices. The company acknowledges that ammonia, even that produced by its green system, must be handled with care to prevent environmental damage… But many farmers often mismanage the production, storage and spreading of manure, a natural source of ammonia… FuelPositive aims to solve this problem by eliminating the carbon emissions associated with the manufacturing of ammonia used for fertilizer, and applying it through deep injection into the ground, providing the most efficient transfer of nitrogen into the soil, with the least impact from nitrous oxides.” To view the full article, visit https://ibn.fm/Ugn89

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Friday's trading session at $0.0995, up 0.302419%, on 284,374 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.088765/$0.24.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

REZYFi is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. The company is targeting markets that include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based and project-specific financings – like solar installations and real estate development. “The company is positioned as one of the first cannabis mortgage bankers in the United States, an arena where most traditional lenders remain reticent to serve state-licensed cannabis companies. To overcome many of the challenges that the companies in the cannabis industry face, REZYFi plans to utilize its corporate strengths to facilitate growth, namely experience, a network of independent brokers, and proprietary technology,” a recent article reads. “REZYFi operates through its two wholly owned subsidiaries from its base of operations in Miami, Florida. The first, REZYFi Lending, primarily addresses the emerging real-estate related financing opportunities within the targeted industry. The second, ResMac Inc., is the company’s traditional mortgage origination, correspondent and servicing option.” To view the full article, visit https://ibn.fm/equ4R

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.

Operations

REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.


Recent News

chart

QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

QSAM Biosciences (OTCQB: QSAM) is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “With the overall incidence of childhood cancer on the rise, the work of QSAM is becoming increasingly important… According to Children’s Cancer Cause, in 2022, an estimated 10,470 children (from birth to 14 years) and 5,480 adolescents (aged 15 to 19 years) will be diagnosed with cancer. ‘It is estimated that there will be 13.7 million cases of childhood cancer between 2020-2050. Unless there are major improvements in diagnosis and treatments, of this, 45% will go undiagnosed and 11.1 million will die if no further investments in interventions are made. The vast majority, almost 85%, will be concentrated in developing countries.’ The group went on to note that cancer in children and young adults is different from cancer that develops in adults,” a recent article reads. “QSAM Biosciences is working to make a difference in this space, as well as in the adult cancer sector. The company is developing ‘targeted therapeutic radiopharmaceuticals as safer and more efficacious alternatives to current treatment modalities to address large unmet medical needs and underserved patient populations.’ With that in mind, QSAM is focused on creating a pipeline of novel radiotherapeutics to serve multiple indications.” To view the full article, visit https://ibn.fm/Q027U

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.

CycloSam®

CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Friday's trading session at $5.96, even for the day, on 200 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.50/$15.972.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) , Canada’s renewable natural gas (“RNG”) infrastructure platform, has entered an agreement with a leading investor relations and capital markets advisory firm: Adelaide Capital. The agreement outlines a partnership between the two companies in which Adelaide will provide investor relations and consulting services to EVGN. A full-service investor relations firm, Adelaide has gained a reputation for bringing a unique and powerful perspective to its client relationships, as well as following a re-engineered investor relations business model. According to the announcement, Adelaide and EverGen Infrastructure will work together to develop and execute a comprehensive capital markets program; Adelaide will also assist with non-deal roadshows, virtual campaigns, conferences and investor communication. The contract calls for EverGen to pay Adelaide C$10,000 a month, along with 15,000 stock options at an exercise price of $2.75 per share and a three-year term; the agreement is subject to the approval of Evergen’s board of directors. “We are thrilled to be working with Adelaide Capital who will provide us with a comprehensive investor relations platform and help strengthen our communication with current and prospective shareholders as we pursue our next leg of growth,” said EverGen Infrastructure CEO Chase Edgelow in the press release. To view the full press release, visit https://ibn.fm/YGAF7

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Friday's trading session at $2, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $2.00/$4.21.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

Todd Michaels, Correlate’s President and CEO, shared some insights into the company’s operations, how it came to be, and its plan for the future. He also shared his journey into the clean energy space

He emphasized that the company is committed to helping corporations and companies to generate clean energy on-site and set up better technology that guarantees an instant increase in NOI

Todd mentioned that Correlate looks to make it increasingly simple for people to find the company and take advantage of its offerings. This, he noted, would be facilitated by the company’s ever-growing team of experts, as well as its technology

Correlate has two or three more acquisitions in the queue, which will be integral in expanding the company’s overall footprint and capabilities. These acquisitions will also aid in the company’s efforts to create new product packaging and delivery while also exploring other markets, mainly Hawaii

Correlate Infrastructure Partners (OTCQB: CIPI) , a portfolio-scale real estate platform focused on eliminating barriers for large-scale property owners looking to improve their Net Operating Income (“NOI”), has achieved tremendous growth over the past couple of years. This growth has been primarily attributed to the company’s understanding of the renewable energy market and the competence of its leadership, starting with Todd Michaels, Correlate’s President and Chief Executive Officer (“CEO”).

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.

Subsidiaries

Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Friday's trading session at $1.5, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.32/$3.25.

Recent News

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF)

The QualityStocks Daily Newsletter would like to spotlight Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) .

California’s Consumer Privacy Act, Privacy Rights Act, and Europe’s General Data Protection Regulation represent a changing data market

Reklaim is a leader in compliant data with a comprehensive platform that allows consumers to re-take control of their data and be compensated should they decide, it can be bought and sold

Reklaim’s revenue jumped 277% year-over-year to $645,008 in Q2 as the company grows organically and explores accretive M&A opportunities

In years gone by, not long ago, companies were quietly hoarding as much data as possible from consumers, then promptly selling it for the maximum amount with little to no concern if the consumer liked it or not. Thankfully, a paradigm shift is happening with new privacy laws in North America, namely the California Consumer Privacy Act (“CCPA”) and the California Privacy Rights Act (“CPRA”), and Europe with its General Data Protection Regulation (“GDPR”), paving the way for litigation against data companies if they don’t comply. That has created an opportunity for companies like Reklaim (TSX.V: MYID) (OTCQB: MYIDF) to burst on the scene with an innovative privacy-compliant identity ecosystem.

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) offers a privacy-compliant identity ecosystem both online (www.ReklaimYours.com) and via a mobile app on iOS and Android in the U.S and Canada. Reklaim believes that consumers own their data and, consequently, have the right to access their online data and choose how it is used, whether for compensation or privacy. Reklaim gives consumers visibility regarding how their data is collected and compensates them for its use, all while also providing advertisers and brands with a source of data compliant with emerging privacy regulations.

The company is driven by the evolution of privacy and how it impacts consumers and companies. Reklaim sells compliant, zero-party data to Fortune 500 brands, platforms, and data companies so that they can offset the risk of non-compliance. ‘Zero-party data’ is data that a consumer proactively and intentionally shares with an organization. This contrasts with ‘third-party data,’ which organizations have collected unbeknownst to consumers for more than 20 years. Zero-party data is the most valuable data in the US$200B data market, as it provides organizations with explicit consumer opt-in vs. through an intermediary such as a data broker.

Reklaim empowers consumers to take back control of their data. The company allows consumers to visit the platform, confirm their identity, and uncover their data that has been collected and sold for years without their explicit consent. Consumers can add, edit or delete data that is associated with their profile and choose which pieces of data they would be willing to share for weekly compensation. Reklaim is the only company in the world today providing consumers with both access to their data that is circulating in the market and a guaranteed weekly paycheck. Alternatively, for users who do not want to sell their data, users can choose to protect their data and subscribe to a suite of subscription-based (SaaS) privacy tools that obfuscate the location of their device when browsing on a mobile phone and alert them when a third-party source has leaked their data or passwords.

Reklaim was founded in 2018 and is based in New York, with offices in Toronto.

Business Model

Reklaim’s primary revenue-generating operations stem from selling consented consumer data to companies and resellers that need data that is compliant with all applicable consumer privacy laws and regulations, including the California Consumer Privacy Act (CCPA). Major Fortune 500 customers and enterprise data platforms have validated Reklaim’s zero-party data and have added this data to their marketplaces and decision-making. Reklaim has sales across three core verticals: brands and agencies that buy advertising, platforms that sell data to Fortune 500 clients, and companies whose primary business is selling data to business customers.

  • Companies & Agencies that Buy Advertising – These customers use Reklaim’s compliant data to inform their media decisions in social, connected television, programmatic and other verticals. Sales cycles are short at about 30 days. Reklaim customers in this segment are Microsoft, Amgen, Bayer, UPS, and Hasbro, to name a few.
  • Platforms that Sell Data – Reklaim has integrated its zero-party data into 15 of the largest enterprise data platforms in the world. These platforms act as the ‘grocery stores’ of data, where the Fortune 500 come to make their data purchases. Reklaim’s data has been validated and added to these platforms, providing ubiquitous distribution of Reklaim data across the data ecosystem. Due to data quality verification and technical requirements, sales cycles are typically longer, about 60-90 days. Customers include LiveRamp, Transunion, Google, The Trade Desk, Lotame, and T-Mobile.
  • Data Companies that Sell Data – These customers need to purchase compliant data to continue offering data to their clients. Sales cycles often last 90-120 days, but these contracts are typically annual, have the highest value, and auto-renew. An example is Nielsen, the television measurement company.

Market Outlook

The data industry, valued at $245 billion in the U.S. and more than $400 billion globally, is being disrupted, and Reklaim is positioned to benefit from the destructive shift.

The disruption is driven by two factors: (1) technology is reducing access to core data that the industry has become dependent upon, and (2) government intervention is emerging through laws and regulations intended to protect consumer data privacy.

Over the past 20 years, the data industry has harvested and exploited consumer data without consumers’ express consent. However, the legal and regulatory environment surrounding consumer data acquisition is rapidly evolving, placing the consumer at the center of emerging privacy policies.

The European Union’s General Data Protection Regulation (GDPR) was rolled out in 2019, followed shortly by the CCPA and the California Privacy Rights Act. More recently, the Canadian Privacy Protection Act, Brazil’s General Data Protection Law, India’s Information Technology Act, and South Africa’s Protection of Personal Information have continued the trend. As a result, industries and companies currently relying on unconsented consumer data will experience a regulation-driven disruptive migration, forcing them sooner rather than later to use only fully consented data sources. This consumer data environment is driving companies to Reklaim to replace their current data providers.

While privacy policies continue to iterate to include the consumer, Big Tech, namely Apple and Google, are increasingly removing data from the market that brands and companies have relied on. Apple’s introduction of Advanced Ad Tracing (ATT) has impacted companies’ ability to track consumer behavior across applications. Facebook, in Q4 2021, was forced to accept a US$10B write down on revenue projections due to this change and is expecting a similar US$10B right down again in 2022.

Google is making similar changes, the most significant being the removal of the third-party cookie from its Chrome browser, which has a 65% market share. This third-party cookie is responsible for the tracking that websites use to monetize by tracking consumers. The removal of the Chrome cookie will put the 1.8 billion websites operating in the open web today under pressure to find a solution to replace the 65% loss in revenue.

Management Team

Neil Sweeney is Chairman and CEO of Reklaim. He has more than 20 years in the industry, with an established reputation for visionary entrepreneurship and an ability to develop technologies. Technologies Sweeney created are used by Fortune 500 brands like Coca-Cola, Lowe’s, Walmart, General Motors, Unilever, and Mondelez. They are the core component of top media demand-side platforms, including Adelphic, The Trade Desk, AppNexus, MediaMath, and Triton Media. He is a two-time finalist for Ernst & Young’s ‘Entrepreneur of the Year’ and received Deloitte’s ‘Fast 50’ award for three consecutive years for the growth of organizations he created.

Ira Levy is CFO at Reklaim. He has over 15 years of experience in a wide range of high-growth, early-stage public and private companies. Most recently, he held the roles of Corporate Controller at VIVO Cannabis Inc. (TSX: VIVO) and Senior VP/Head of Finance for start-up Honest Inc. (d/b/a Province Brands of Canada). He has also acted as an advisor for startup AI companies through the Creative Destruction Lab Program. He received his MBA in Accounting and Finance from the Schulich School of Business at York University and is a Chartered Professional Accountant.

Jake Phillips is Chief Technical Officer at Reklaim. He is a proven technology leader who excels at bridging the gap between innovation and business in dynamic environments. He has gained a breadth of industry knowledge across telco/cable, banking, and client services. His professional experience spans enterprise integration, mobility, big data, cloud operations, and data security.

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF), closed Friday's trading session at $0.0535, even for the day. The average volume for the last 3 months is 21,550 and the stock's 52-week low/high is $0.04495/$0.3859.

Recent News

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (OTC: SGMD).

SGMD inks MSA with California cannabis micro license holder

Agreement “lays a foundation for a significantly expanded manufacturing and distribution infrastructure,” says CEO

Key partnerships are essential pieces of Sugarmade’s focus on California cannabis space

With the recent signing of a management services agreement (“MSA”) ( https://cnw.fm/7zHND ), Sugarmade (OTC: SGMD) is making key progress toward the goal of strengthening its position in the California cannabis space. SGMD signed the MSA through its subsidiary, SugarRush, which entered into the agreement with Canndis Inc., a California cannabis micro license holder.

Sugarmade, Inc. (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources.

The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.

Brand Portfolio

Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

  • NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
  • BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company

On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc.

The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total.

Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience.

“The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Market Opportunity

The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018.

Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020.

The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share.
Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward.

Management

Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Sugarmade, Inc. (OTC: SGMD), closed Friday's trading session at $0.0003, even for the day, on 28,377,344 volume. The average volume for the last 3 months is 28.377M and the stock's 52-week low/high is $0.0002/$0.002.

Recent News

Tingo Inc. (OTCQB: TMNA)

The QualityStocks Daily Newsletter would like to spotlight Tingo Inc. (TMNA).

Blockchain technology may have been popularized by the cryptocurrency craze, but it is now being used in a variety of alternative applications. Features such as elevated security and data traceability that made cryptocurrencies such a hit have made blockchain equally popular and resulted in plenty of innovative uses. For example, authorities in Dubai are leveraging blockchain technology to speed up passport recovery efforts. Losing your passport can be a hassle, especially if it happens in a foreign country , and it can take anywhere from eight business days to eight weeks to have the passport replaced. In the United Arab Emirates (UAE), however, blockchain technology will allow you to find your missing passport within 24 hours. According to a statement released by the Dubai police, people will be able to recover their missing passports speedily by submitting a request to obtain a passport certificate. This certificate can be obtained by filing a request to the Dubai Police App, Smart Police Station, or the official police website . Once the request is approved and you have received a passport certificate, the police will use a service that leverages blockchain technology to locate your passport within 24 hours. The service will collaborate with agencies and courts to issue 30-day certificates and will be available to UAE citizens, residents, diplomats and visitors from GCC countries . As companies such as Tingo Inc. (OTC: TMNA) also take blockchain technology into the agricultural sector, there seems to be no stop to the onward march of these technologies into every sector of human life.

Tingo Inc. (OTCQB: TMNA) is a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa. The company aims to be Africa’s leading agri-fintech player, transforming rural farming communities to connect through its proprietary platform to meet their complete needs – from inputs and agronomy to off take and marketplace – and deliver sustainable income in an impactful way. The company’s vision is to build complete digitally inclusive ecosystems that promote financial inclusion and deliver disruptive micro-finance solutions, empower societies, produce social upliftment in rural communities and open international opportunities.

Tingo believes that a truly connected world will help contribute to a better global society. The company’s core focus areas are telecoms, financial services/fintech and agritech. Tingo’s goal is to provide a best-in-class customer experience, support the domestic economies of its host countries and support technological and financial inclusion to end the poverty premium. Through this, Tingo hopes to deliver attractive returns to shareholders while investing in the long-term future of the company and its subsidiaries.

Global climate change is challenging sustainable production and food security. Tingo’s strategy and market execution provide an opportunity for Africa to be a core focal point to solve a number of key areas of concern, including food security, gender equality, financial inclusion and poverty alleviation, to name a few. Disruption of micro finance through the use of DeFi-based stable coins and smart contracts will give agri-communities access to capital markets-driven digital finance solutions that make them more competitive and sustainable economically, striking a good balance of returns between digital asset providers and Tingo as the service partner. This innovation will deliver significant access to much needed finance at ‘Grassroot’ levels, delivering tangible social upliftment and GDP growth in the African markets served by Tingo.

Tingo Mobile, with more than nine million subscribers, is Nigeria’s leading technology and device-as-a-service platform aimed at accelerating digital commerce, especially in the country’s agritech and fintech verticals. The company helps farmers acquire mobile phones through a unique leasing plan, connecting them to mobile and data networks through its own virtual mobile network. Tingo also connects farmers to markets, services and resources via Nwassa, its digital agritech marketplace platform that commenced operations in 2020. The company has also launched a beta version of TingoPay – a B2B and B2C fintech app aimed at providing financial services to users inside and outside of the agriculture value chain. Among the services offered are mobile wallets, payment processing and access to specialist lenders, insurers and pension products.

Tingo will soon announce its innovative blockchain-based solution for use of digital stable coins to empower frictionless trade across borders in Africa. The company’s market-proven model in Nigeria is its core foundation, enabling Tingo to deliver the same service model across Africa to become the continent’s leading agri-fintech business powered through smartphone technology.

The African Continental Free Trade (ACFT) plan will be a key framework to prepare the company to be the leading intra-Africa trading hub for trade flows across Africa in the medium term, when it is likely the agreement will be executed into tangible activity. Tingo is well positioned to easily transform the goals of the ACFT into reality when finally implemented by the African Union and the various African countries that have not signed up.

Tingo posted total revenue of $594 million in 2020, with $212 million EBITDA. As of December 31, 2020, Tingo has 9,344,000 subscribers. The company is confident that these figures will grow through its expansion across Africa and natural progression of business in Nigeria.

Businesses

Tingo has four core businesses:

  • Mobile Phone Leasing – Tingo has distributed almost 30 million mobile handsets since 2014 and will continue to replace the devices of its installed customer base every three years. Tingo Mobile provides the latest mobile phone handsets at an affordable price point and allows customers to spread payments over 36 months.
  • Mobile Voice and Data Service – Through a mobile virtual network, Tingo provides its customers with voice and data services, allowing customers to communicate effectively, both inside and outside the agricultural ecosystem.
  • Nwassa Marketplace Platform – Nwassa is Tingo’s proprietary agritech platform which provides Africa’s farmers with access to global markets to secure more competitive pricing for their crops. The platform processes 500,000 daily transactions with a value of over $8 million. A select group of trusted partners can assist smallholder farmers and agricultural cooperatives with packaging, warehousing, and dry and wet cargo logistics, as well as up-to-date information from the global agricultural sector. Tingo provides its customers with digital wallet services, which enable them to send and receive domestic payments, monitor cash flow in real time and securely hold money. The company also provides access to other services, such as utility bill payment, virtual airtime top-up, insurance services and alternative lending solutions.
  • TingoPay – Since the launch of the Nwassa platform, Tingo has been a dominant player in the B2B fintech vertical. After many successful months of operating Nwassa, Tingo entered the fintech B2C vertical to extend its B2B offering to a broader market beyond agriculture.

TingoPay is still in its beta phase and will launch in 2021 with a comprehensive marketing campaign. TingoPay offers the following services:

  • Tingo Wallet top-up
  • Peer to Peer payments, inclusive of merchant payments at the stores
  • Utility payments – airtime, broadband, cable, electricity, water, hotel, flights etc.
  • Pension payments
  • QR code payment services

Market Opportunity

Africa is the second-largest continent by population. It is also the youngest by far, with a median age of 18 for its 1.3 billion people. Tingo believes the building blocks for growth in Africa’s agriculture industry are in place and that the company is well positioned to participate in the upside. Sub-Saharan Africa’s population is growing at a rate of 2.7 percent per year. At the current growth rate, the continent’s population will double by 2050. Africa’s youthfulness represents a significant opportunity for material growth in demand for agricultural commodities. This younger generation is also being born into a digital world and is comfortable using technology.

Africa’s governments are improving business conditions for entrepreneurs and small businesses. Sub-Saharan Africa’s World Bank Doing Business rank has improved from 45 in 2004 to 65 in 2020. Tingo believes this trend will continue and encourage establishment of more new ventures across all economic sectors, including agriculture.

Africa attracted $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018. Investments are increasingly focused on services and industrial sectors. Only 20 percent of investments are in extractive industries – a clear reversal from 2008, when 55 percent of FDI was aimed at resource extraction. Tingo believes FDI into Africa will help resolve significant infrastructure constraints and create value for agribusiness.

Management Team

Dozy Mmobuosi is the CEO of Tingo. He cofounded Tingo Mobile PLC (Nigeria) in 2001 and led the design and launch of Nigeria’s first SMS banking solution, which is still in use in the country today. He also headed a team of more than 120 Chinese and Nigerian engineers in the construction of two mobile phone assembly plants in Nigeria, which have produced and distributed 20 million phones across the country. He has led Tingo’s growth to more than $600 million in revenue annually. He holds a Ph.D. in Rural Advancement from UPM Malaysia.

Dakshesh Patel is the CFO of Tingo. He was formerly CFO of NatWest’s Global Debt and Investment Banking division. He has served as a Director at Gerken Capital Associates, a San Francisco-based alternative asset fund manager. He also led the restructure of Lloyds Banking Group (last financial crisis); managed integration of two leading shipping groups’ global treasury function to create world-leading shipping group Maersk Shipping; built three fintech companies; and exited one to Worldpay. Mr. Patel has strong banking experience, with a focus on Africa. He is a chartered accountant.

Chris Cleverly is president of Tingo. He has served as CEO of the Made in Africa Foundation, and as CEO of blockchain payments gateway startup Kamari. He has been a board member of several companies, both public and private, in the UK, India, China and Africa. He has advised multiple UK companies on their entrance into African markets, and regularly advises the UK Government on development issues and African governments on investment issues.

Clarence Simms is the Chief Technology Officer at Tingo. He has 25 years of IT and IT management experience. He has worked in IT Shared Services Technical Operations and IT Program Management for Huawei Technologies and MTN. As an entrepreneur, he created Africaprepay.com, a service that allows African Diaspora travelers to send airtime, pay bills, send mobile money and transfer money to a bank account from anyplace in the world.

Rory Bowen is the Chief of Staff at Tingo. Mr. Bowen started his career in traditional capital and derivatives markets working for Moneycorp and Tradition UK in European and emerging markets across FX, interest rate derivative and government bond markets. He has also spent time with one of Europe’s fastest growing fintech’s banking circles. Before joining Tingo, he was Chief of Staff at FinTech Alliance, an organization established in partnership with the UK Government Department for International Trade to foster innovation, growth and foreign direct investment (FDI) in the financial services sector and facilitate greater public/private cooperation.

Tingo Inc. (OTCQB: TMNA), closed Friday's trading session at $1.4, off by 12.5%, on 11,405 volume. The average volume for the last 3 months is 11,405 and the stock's 52-week low/high is $0.3727/$6.00.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.